- Home
- PTMN vs PLX Comparison
PTMN vs PLX Comparison
Compare PTMN & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PTMN
- PLX
- Stock Information
- Founded
- PTMN 2006
- PLX 1993
- Country
- PTMN United States
- PLX Israel
- Employees
- PTMN N/A
- PLX N/A
- Industry
- PTMN Finance: Consumer Services
- PLX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- PTMN Finance
- PLX Health Care
- Exchange
- PTMN Nasdaq
- PLX Nasdaq
- Market Cap
- PTMN 152.6M
- PLX 160.2M
- IPO Year
- PTMN N/A
- PLX 1998
- Fundamental
- Price
- PTMN $16.77
- PLX $2.46
- Analyst Decision
- PTMN Hold
- PLX
- Analyst Count
- PTMN 3
- PLX 0
- Target Price
- PTMN $19.33
- PLX N/A
- AVG Volume (30 Days)
- PTMN 34.7K
- PLX 581.3K
- Earning Date
- PTMN 03-13-2025
- PLX 03-13-2025
- Dividend Yield
- PTMN 16.48%
- PLX N/A
- EPS Growth
- PTMN N/A
- PLX N/A
- EPS
- PTMN 0.39
- PLX N/A
- Revenue
- PTMN $65,828,000.00
- PLX $45,667,000.00
- Revenue This Year
- PTMN N/A
- PLX N/A
- Revenue Next Year
- PTMN N/A
- PLX $90.00
- P/E Ratio
- PTMN $43.41
- PLX N/A
- Revenue Growth
- PTMN N/A
- PLX N/A
- 52 Week Low
- PTMN $15.94
- PLX $0.82
- 52 Week High
- PTMN $20.84
- PLX $2.53
- Technical
- Relative Strength Index (RSI)
- PTMN 54.46
- PLX 79.21
- Support Level
- PTMN $16.05
- PLX $2.11
- Resistance Level
- PTMN $16.88
- PLX $2.36
- Average True Range (ATR)
- PTMN 0.23
- PLX 0.12
- MACD
- PTMN 0.09
- PLX 0.02
- Stochastic Oscillator
- PTMN 73.71
- PLX 90.35
About PTMN Portman Ridge Finance Corporation
Portman Ridge Finance Corp Inc is a non-diversified closed-end investment company. The company originates, structures, and invests in secured term loans, bonds or notes, and mezzanine debt primarily in privately-held middle market companies but may also invest in other investments such as loans to publicly traded companies, high-yield bonds, and distressed debt securities. The company's investment objective in the Debt securities portfolio is to generate current income and, to a lesser extent, capital appreciation from the investments in senior secured term loans, mezzanine debt, and selected equity investments in privately-held middle market companies.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.